The US Court of Appeals for the Federal Circuit affirmed a district court’s noninfringement determination, finding that the presence of a disclaimed compound in the accused product precluded infringement. Azurity Pharm., Inc....more
4/17/2025
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Claim Construction ,
Disclaimers ,
Doctrine of Prosecution Disclaimer ,
Generic Drugs ,
Hatch-Waxman ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents